SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
LINK WILLIAM J PHD

(Last) (First) (Middle)
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 109

(Street)
PRINCETON NJ 08540

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/30/2019
3. Issuer Name and Ticker or Trading Symbol
Oyster Point Pharma, Inc. [ OYST ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.001 per share 2,018 I See footnotes(1)(3)
Common Stock, par value $0.001 per share 320,439 I See footnotes(2)(3)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock (4) (4) Common Stock, par value $0.001 per share 10,420 (4) I See footnotes(1)(3)
Series A Convertible Preferred Stock (4) (4) Common Stock, par value $0.001 per share 1,654,359 (4) I See footnotes(2)(3)
Series B Convertible Preferred Stock (4) (4) Common Stock, par value $0.001 per share 955,392 (4) I See footnotes(5)
Explanation of Responses:
1. Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV").
2. Shares held by Versant Venture Capital IV, L.P. ("Versant IV").
3. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
4. These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") will automatically be converted into shares of Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock has no expiration date.
5. Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C.
Remarks:
Exhibit 24 - Power of Attorney
/s/Jeffrey Nau, Attorney-in-fact 10/30/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                               POWER OF ATTORNEY

    The undersigned, as a Section 16 reporting person of Oyster Point Pharma,
Inc. (the "Company"), hereby constitutes and appoints Jeffrey Nau and Daniel
Lochner and each of them, as the undersigned's true and lawful attorney-in-fact
to:

    1.  complete and execute Forms 3, 4 and 5 and other forms and all amendments
        thereto as such attorney-in-fact shall in his discretion determine to be
        required or advisable pursuant to Section 16 of the Securities Exchange
        Act of 1934 (as amended) and the rules and regulations promulgated
        thereunder, or any successor laws and regulations, as a consequence of
        the undersigned's ownership, acquisition or disposition of securities of
        the Company; and

    2.  do all acts necessary in order to file such forms with the Securities
        and Exchange Commission, any securities exchange or national
        association, the Company and such other person or agency as the
        attorneys-in-fact shall deem appropriate.

    The undersigned hereby ratifies and confirms all that said attorneys-in-fact
and agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 8th day of October, 2019.

                                    Signature:  /s/  William J. Link
                                               ----------------------
                                    Print Name: William J. Link